about
Long-term exposure to air pollution and incidence of cardiovascular events in womenMultivitamin use and risk of cancer and cardiovascular disease in the Women's Health Initiative cohortsIncidental genetic findings in randomized clinical trials: recommendations from the Genomics and Randomized Trials Network (GARNET).Efficacy of yoga for vasomotor symptoms: a randomized controlled trialReanalysis of the Women's Health Initiative oral contraceptive data reveals no evidence of delayed cardiovascular benefit.Effects of blood collection conditions on ovarian cancer serum markers.Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects.Body mass index, physical activity, and mortality in women diagnosed with ovarian cancer: results from the Women's Health Initiative.Efficacy of omega-3 for vasomotor symptoms treatment: a randomized controlled trial.The effects of postmenopausal hormone therapy on serum estrogen, progesterone, and sex hormone-binding globulin levels in healthy postmenopausal women.Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: a modeling study.Intraindividual variability over time in plasma biomarkers of inflammation and effects of long-term storageLow-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial.The Women's Health Initiative recruitment methods and results.Menopausal hormone therapy and cancer: changing clinical observations of target site specificity.Lessons learned from the Women's Health Initiative trials of menopausal hormone therapy.Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial.Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy.Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.The women's health initiative: lessons learned.Breast cancer after use of estrogen plus progestin in postmenopausal women.The case for early detection.Optimal cutoffs of obesity measures in relation to cancer risk in postmenopausal women in the Women's Health Initiative StudyObesity and inflammation markers in relation to leukocyte telomere length in a cross-sectional study of persons with Barrett's esophagusPooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms.Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trialEffects of a dietary intervention and weight change on vasomotor symptoms in the Women's Health Initiative.Use of alternative time scales in Cox proportional hazard models: implications for time-varying environmental exposures.Statistical issues arising in the Women's Health Initiative.Migraine history, nonsteroidal anti-inflammatory drug use, and risk of postmenopausal endometrial cancerBody mass index, physical activity, and survival after endometrial cancer diagnosis: results from the Women's Health Initiative.Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701)Breast tenderness after initiation of conjugated equine estrogens and mammographic density change.Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone women's health initiative clinical trialsRisk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communitiesAmbient particulate air pollution and ectopy--the environmental epidemiology of arrhythmogenesis in Women's Health Initiative Study, 1999-2004.Ambient fine particulate matter exposure and myocardial ischemia in the Environmental Epidemiology of Arrhythmogenesis in the Women's Health Initiative (EEAWHI) studyMethods for the design of vasomotor symptom trials: the menopausal strategies: finding lasting answers to symptoms and health networkSouthwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer
P50
Q28286071-57A4E5F2-C8E3-4DB6-9C48-7ED3F2EA5ED2Q28308282-722FE8DB-EF8A-43D8-9950-A3F19C462713Q30418252-5CB74CEA-5C51-4311-8C5B-315625982469Q30560613-0AEF84BC-F256-4D6C-B87B-87624DBCBAC8Q30986838-B9E22EF9-D4F1-42C4-A445-E9FE367DD22CQ33308744-2E44C195-AF8B-48E1-9961-5489F52D8F70Q33717993-C9A94B4F-3B18-4EA8-AD33-678753A39E18Q33739861-B5CE475E-DE05-4EA0-99A4-E3AE22634319Q33783215-6B9FB7D3-0EF3-40E4-98F8-842D0C2943C9Q33810759-263DAD43-704D-45BF-BC4D-2FA3C118E26EQ33838504-2C68F4C4-5267-4C69-A959-5A8E2E382AF4Q34147730-9F6FFFFA-B138-4E82-AA83-260F1B61503CQ34213725-AB413FDD-0AE5-4A5B-9745-FFD378A1E967Q34266113-CFB84F3F-79CF-414C-9E4D-93137C24AEFBQ34272010-725DCECC-820A-48DF-9EAB-E67FC214B44CQ34315478-79E32132-4003-4EFA-BBB4-B94AEF42934DQ34319242-5259281E-B733-4EDB-927F-A32CCCE5AD88Q34370566-8CF4AB69-1CBE-459C-A9B2-EC17C4678831Q34512916-1A12599C-984D-4571-967D-E5C292FAE6C6Q34543818-18FAB2A6-B8CF-447F-9220-4A3190280FA6Q34762689-CFD225F3-5890-4A3B-BAA8-8B63A5A316A1Q34938322-7F822C1F-9F32-487F-A7A1-CF8699097035Q35097361-D8E3D989-63FA-434B-A6AB-C6286814AA76Q35188724-56C88CA7-4B61-4FD2-BCA5-5801A00E2C6BQ35778939-BE30B0EB-CEC8-47CF-8BFB-67A50E7D1A14Q35919965-9A9A8CBE-68A7-44F4-9129-82AC9A09C202Q36143058-424FD4A7-EF49-4F7D-BC17-0F9825993FE5Q36191949-0D20F58E-765F-4925-8C12-47E0C086D322Q36310007-793E4E39-09A9-4430-BB05-43AE7CB20DA4Q36364054-5B19EEB6-7B5D-4276-89CF-77A138043273Q36384972-5B12704D-3F3C-42DB-88DE-BD702B99D76DQ36553497-1ED8A921-A086-4CC2-AF1B-9139E85A3667Q36819921-27B0AA8F-554F-4D40-9679-21B570D53C4DQ36937185-4873D2F4-454A-4A01-9A7D-75413861EDC0Q36971892-6DEB35F5-5921-4EB6-B4F7-CB5CD62B52D4Q36972107-301A42A4-9D22-4A59-B7A8-025154BFDF96Q36982640-D5EDF922-C6F8-4C17-8AE8-7BAC81D6C103Q37201194-DE918E38-10C8-4D4F-A8FA-98E26DE50DC2Q37228688-6C6D0235-2E3C-481E-895D-CC6EF38A51DDQ37245146-E96BC770-D8C4-4FD6-A6E0-24C36946F1EE
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Garnet L Anderson
@ast
Garnet L Anderson
@en
Garnet L Anderson
@es
Garnet L Anderson
@nl
Garnet L Anderson
@sl
type
label
Garnet L Anderson
@ast
Garnet L Anderson
@en
Garnet L Anderson
@es
Garnet L Anderson
@nl
Garnet L Anderson
@sl
prefLabel
Garnet L Anderson
@ast
Garnet L Anderson
@en
Garnet L Anderson
@es
Garnet L Anderson
@nl
Garnet L Anderson
@sl
P106
P21
P31
P496
0000-0001-5087-7837